Northern Biologics Inc. Company Profile
Northern Biologics was launched in June 2014 from Blueline Bioscience, a
Canadian biotechnology incubator operated by venture capital firm
Versant Ventures, in partnership with the University of Toronto and
University Health Networkâs Princess Margaret Cancer Centre.
Headquartered in the MaRS Discovery District of Toronto, the company is
developing a portfolio of antibody-based therapeutics based on relevant
targets in the tumor microenvironment. Learn more at
northernbiologics.com.
News Articles
Applied BioMath supporting Ph I trial of Northern Biologics’ lead antibody therapeutic
Applied BioMath is providing clinical pharmacology and semi-mechanistic PK/PD modeling support for Northern Biologics Phase I clinical trial.
Another build for WuXi Biologics with $240m investment in Northern China
CDMO WuXi Biologics has announced plans to build a biologics centre in China, where it will develop and manufacture large molecule drugs for clinical and commercial production.
Northern Biologics’ Rahul Ballal Joins Imara as CEO
Rahul Ballal has been named CEO of Cambridge drug developer Imara. Ballal most recently served as chief business officer of Northern Biologics. Imara launched in 2016 backed by $31 million in financin...
WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang
WuXi Biologics will build a $240 million CDMO facility in Shijiazhuang, the capital of China's northern Hebei province. The new facility is an addition to WuXi Biologics' existing CDMO facilities in S...
WuXi Biologics Invests $60 Million in Another New Plant -- In Singapore This Time
WuXi Biologics will spend $60 million to build a biologics CDMO plant in Singapore. The facility will be WuXi Biologics' tenth manufacturing plant globally and the third new facility it has announced ...
WuXi Biologics will invest $60 million to build a state-of-the-art biologics CDMO operation in the greater Boston area, the fourth new manufacturing project WuXi has announced in the last two months. ...
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United ...
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing Read ...
WuXi Biologics Plans Big Increase in Manufacturing Capacity
Over the past month, WuXi Biologics has announced three new manufacturing plants, two of them outside of China -- the first time it has located manufacturing plants in a foreign country. The new facil...
Drugs and Medications
Helium [Airgas Northern California and Nevada, Inc.]
helium
Oxygen [Northern Welding Supply]
Liquid Oxygen Label
Air [Airgas Northern California and Nevada, Inc.]
air
Oxygen [Northern Welding Supply]
Compressed Oxygen Label
Nitrogen [Northern Welding Supply]
Liquid Nitrogen Label
PubMed Articles
Biologics for pityriasis rubra pilaris treatment: a review of the literature.
Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease, often refractory to conventional therapies. The off-label use of biologics, such as anti-TNF, -IL-12/IL-23, -IL-17 ag...
Biologics containing growth factors are frequently used to enhance healing after musculoskeletal injuries. One mechanism of action is thought to be though the ability of biologics to induce homing and...
Long-term clinical effectiveness of biologics in psoriasis is needed.
Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.
Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.
Dosing considerations for inhaled biologics.
The number of biologics in the therapeutic development pipeline is increasing including those delivered though inhalation (Morales, 2017; Fathe, 2016). Biologics comprise a broad variety of complex ma...
Clinical Trials
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...
Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease
"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...
Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity
Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.
Companies
Northern Biologics was launched in June 2014 from Blueline Bioscience, a Canadian biotechnology incubator operated by venture capital firm Versant Ventures, in partnership with th...
NOM's aim is to make a contribution to the sustained improvement of the economic structure and employment in the Northern Netherlands. And if you would like to know what the possibilities and the uniq...
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...
Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...
Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...
More Information about "Northern Biologics Inc." on BioPortfolio
We have published hundreds of Northern Biologics Inc. news stories on BioPortfolio along with dozens of Northern Biologics Inc. Clinical Trials and PubMed Articles about Northern Biologics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Northern Biologics Inc. Companies in our database. You can also find out about relevant Northern Biologics Inc. Drugs and Medications on this site too.
